Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 20/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Remikiren SCHEMBL22263508 | 1.00 | REN (0.76) | REN | |
| Remikiren SCHEMBL12921169 | 1.00 | REN (0.76) | REN | |
| Remikiren SCHEMBL12921156 | 1.00 | REN (0.76) | REN | |
| Remikiren SCHEMBL8352030 | 1.00 | REN (0.76) | REN | |
| Remikiren SCHEMBL8352292 | 1.00 | REN (0.76) | REN | |
| Remikiren SCHEMBL9556439 | 1.00 | REN (0.76) | REN | |
| Remikiren SCHEMBL7303589 | 1.00 | REN (0.76) | REN | |
| Remikiren SCHEMBL9556708 | 1.00 | REN (0.76) | REN | |
| SCHEMBL7328547 | 0.99 | REN (0.74) | REN | |
| SCHEMBL7292222 | 0.99 | REN (0.74) | REN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1369 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250206779-A1 | ANGIOTENSIN-(1-9) ANALOGUE BASED ON D AMINO ACIDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | UNIVERSIDAD DE CHILE (CL) | 2025-06-26 | — | — | US | claimed |
| WO-2025050228-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A PEPTIDE OR A COMBINATION OF PEPTIDES AGONISTIC TO THE MAS, AT1 AND AT2 RECEPTORS | PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE (CL) | 2025-03-13 | — | — | WO | claimed |
| US-20250082608-A1 | TREATMENT AND PREVENTION OF GLOMERULAR DISEASE | SINGAPORE HEALTH SERVICES PTE LTD. (SG) | 2025-03-13 | — | — | US | claimed |
| EP-4448096-A1 | TREATMENT AND PREVENTION OF GLOMERULAR DISEASE | Singapore Health Services Pte. Ltd. (SG) | 2024-10-23 | — | — | EP | claimed |
| EP-4337675-A1 | ANGIOTENSIN-(1-9) ANALOGUE BASED ON D AMINO ACIDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | Universidad De Chile (CL) | 2024-03-20 | — | — | EP | claimed |
| US-20240002935-A1 | GENETIC METHOD FOR DIAGNOSIS AND TREATMENT OF PRE AND POST CORONAVIRUS INFECTIONS | GENETICURE INC. | 2024-01-04 | — | — | US | claimed |
| WO-2023183932-A2 | MONOBODIES BINDING TO INTERCELLULAR ADHESION MOLECULE 2 (ICAM-2) | NEW YORK UNIVERSITY (US) | 2023-09-28 | — | — | WO | claimed |
| WO-2023111196-A1 | TREATMENT AND PREVENTION OF GLOMERULAR DISEASE | SINGAPORE HEALTH SERVICES PTE. LTD. (SG) | 2023-06-22 | — | — | WO | claimed |
| EP-4132653-A1 | GENETIC METHOD FOR DIAGNOSIS AND TREATMENT OF PRE AND POST CORONAVIRUS INFECTIONS | Geneticure Inc. (US) | 2023-02-15 | — | — | EP | claimed |
| WO-2022265697-A1 | COMPOSITIONS FOR TREATING VIRAL INFECTIONS AND METHODS FOR SAME | Tiger Development, LLC (US) | 2022-12-22 | — | — | WO | claimed |
| WO-2005037317-A2 | MAST CELL-DERIVED RENIN | CORNELL RESEARCH FOUNDATION, INC. (US) | 2005-04-28 | — | — | WO | claimed |
| WO-2005025673-A1 | MULTI-SYSTEM THERAPY FOR DIABETES, THE METABOLIC SYNDROME AND OBESITY COMPRISING A HYPOGLYCEMIC AGENT | FOLLI FRANCO (IT) | 2005-03-24 | — | — | WO | claimed |
| US-20050065184-A1 | Method of reducing the risk of oxidative stress | AAIPHARMA INC. | 2005-03-24 | — | — | US | claimed |
| US-20050054731-A1 | Includes a biguanide hypoglycemic agent, a lipid lowering agent, a blood pressure lowering agent and, preferably, an anti-platelet agent | FOLLI FRANCO (IT) | 2005-03-10 | — | — | US | claimed |
| WO-2005020984-A2 | METHOD OF REDUCING THE RISK OF OXIDATIVE STRESS | AAIPHARMA INC. (US) | 2005-03-10 | — | — | WO | claimed |
| US-20040266743-A1 | Combination of an aldosterone receptor antagonist and a renin inhibitor | PHARMACIA CORPORATION | 2004-12-30 | — | — | US | claimed |
| WO-2004100871-A2 | COMBINATION OF AN ALDOSTERONE RECEPTOR ANTAGONIST AND A RENIN INHIBITOR | PHARMACIA CORPORATION (US) | 2004-11-25 | — | — | WO | claimed |
| US-5981470-A | ADMINISTERING PHARMACEUTICAL AGENT SELECTED FROM THE GROUP CONSISTING OF AN ANGIOTENSIN CONVERTING ENZYME INHIBITOR, AN ANGIOTENSIN II-RECEPTOR ANTAGONIST, A RENIN INHIBITOR, AND AN ANGIOTENSIN II-RECEPTOR EXPRESSION INHIBITOR | THE UNIVERSITY OF BIRMINGHAM (GB) | 1999-11-09 | — | — | US | claimed |
| EP-0764021-A1 | UTERINE FIBROID TREATMENT | THE UNIVERSITY OF BIRMINGHAM (GB) | 1997-03-26 | — | — | EP | claimed |
| WO-1995033454-A1 | UTERINE FIBROID TREATMENT | THE UNIVERSITY OF BIRMINGHAM (GB) | 1995-12-14 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040266743-A1 | Combination of an aldosterone receptor antagonist and a renin inhibitor | REN, AGTR1, AGTR2 | REN 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.